Evotec To Continue Muscular Dystrophy Work with Jain
Specific terms of the extension were not disclosed. The firms began working together in 2012 with the aim of developing a cell-based high through-put screening assay designed to assess muscle cells that can be used to identify potential treatments.
Evotec COO Marion Polywka said: “This collaboration highlights both the increasing role that foundations play in delivering solutions for unmet medical needs and also how Evotec's broad and comprehensive discovery platform can be leveraged in support of these goals in a highly efficient and effective manner.”
This enthusiasm was echoed by Plavi Mittal, CEO of the Jain Foundation, who said: 'We are excited to be moving toward screening compound libraries with Evotec. This is an important step toward accomplishing our mission of finding a therapy for Limb-girdle muscular dystrophy.”
